Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s Disease phase Ib/IIa trial. The positive data from its Phase Ib/IIa study indicates that NT-0796 reduces key neuroinflammatory and inflammatory biomarkers in Parkinson’s disease patients to the levels found in healthy elderly controls over 28 days.
The NLRP3 inflammasome is a main mediator of inflammation in many pathologies. NT-0796 selectively inhibits NLRP3, lowering levels of both pro-inflammatory cytokines IL-1β and IL-18. This action delivers therapeutic effects directly to immune cell types responsible for inflammatory diseases, including peripheral and neuroinflammatory diseases.